title: Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.
abstract: Pharmacological management of atrial fibrillation (AF) remains an important unmet medical need. Because available drugs for rhythm control of AF are often associated with a significant risk for development of ventricular arrhythmias or extracardiac toxicity, recent drug development has focused on agents that are atrial selective. Inhibition of the ultrarapid delayed rectifier potassium current (I(Kur)), a current exclusive to atria, is an example of an atrial-selective approach. Recent studies, however, have shown that loss-of-function mutations in KCNA5, the gene that encodes K(V)1.5, the alpha subunit of the I(Kur) channel, is associated with the development of AF and that inhibition of I(Kur) can promote the induction of AF in experimental models. Another potential atrial-selective approach has recently been identified. Experimental studies have demonstrated important atrioventricular differences in the biophysical properties of the sodium channel and have identified sodium channel blockers that can exploit electrophysiological distinctions between atria and ventricles. Atrial-selective/predominant sodium channel blockers such as ranolazine effectively suppress AF in experimental models involving canine-isolated right atrial preparations at concentrations that produce little to no effect on electrophysiological parameters in ventricular myocardium. Chronic administration of amiodarone was also found to exert atrial-selective depression of I(Na)-dependent parameters and thus to prevent the induction of AF. Ranolazine and amiodarone have in common the ability to rapidly dissociate from the sodium channel and to prolong the atrial action potential duration via inhibition of I(Kr). Our observations suggest that atrial-selective sodium channel block may be a fruitful strategy for the management of AF.
authors.affiliation: Masonic Medical Research Laboratory, Utica, NY, USA. ca@mmrl.edu
authors.forename: Charles
authors.initials: C
authors.lastname: Antzelevitch
authors.forename: Alexander
authors.initials: A
authors.lastname: Burashnikov
mesh_terms: D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology*; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects*; D008955:Models, Cardiovascular; D012964:Sodium / Q000378:metabolism*; D026941:Sodium Channel Blockers / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D026941:Sodium Channel Blockers; D012964:Sodium
references.citation: Circulation. 2006 May 23;113(20):2462-72
references.pmid: 16717165
references.citation: Am J Physiol. 1993 Oct;265(4 Pt 2):H1301-9
references.pmid: 8238418
references.citation: Pacing Clin Electrophysiol. 1995 Sep;18(9 Pt 1):1686-704
references.pmid: 7491312
references.citation: J Cardiovasc Pharmacol Ther. 2004 Sep;9 Suppl 1:S65-83
references.pmid: 15378132
references.citation: Circ Res. 1992 Sep;71(3):535-46
references.pmid: 1323431
references.citation: Fundam Clin Pharmacol. 1997;11(5):402-7
references.pmid: 9342593
references.citation: Circulation. 2007 Oct 9;116(15):1647-52
references.pmid: 17804441
references.citation: Am J Cardiol. 1999 Nov 4;84(9A):20R-28R
references.pmid: 10568656
references.citation: J Am Coll Cardiol. 2006 Aug 15;48(4):854-906
references.pmid: 16904574
references.citation: J Cardiovasc Pharmacol. 2008 Aug;52(2):121-8
references.pmid: 18670368
references.citation: Br J Pharmacol. 2008 Mar;153(6):1128-32
references.pmid: 18071302
references.citation: Circulation. 1995 Oct 1;92(7):1954-68
references.pmid: 7671380
references.citation: Expert Opin Investig Drugs. 2007 Apr;16(4):519-32
references.pmid: 17371199
references.citation: Circ Res. 2000 Nov 24;87(11):964-5
references.pmid: 11090538
references.citation: J Cardiovasc Electrophysiol. 2007 Dec;18(12):1313-20
references.pmid: 17916155
references.citation: J Neurosci. 2001 Dec 15;21(24):9629-37
references.pmid: 11739573
references.citation: Heart Rhythm. 2007 Jun;4(6):816-61
references.pmid: 17556213
references.citation: Ann Noninvasive Electrocardiol. 2009 Jul;14(3):290-300
references.pmid: 19614642
references.citation: Ann N Y Acad Sci. 2008 Mar;1123:105-12
references.pmid: 18375582
references.citation: J Atr Fibrillation. 2008;1(2):98-107
references.pmid: 21057583
references.citation: J Cardiovasc Pharmacol. 2008 Aug;52(2):105-20
references.pmid: 18670369
references.citation: J Cardiovasc Pharmacol. 2008 Oct;52(4):300-5
references.pmid: 18841075
references.citation: J Mol Cell Cardiol. 2001 May;33(5):923-32
references.pmid: 11343415
references.citation: Indian Pacing Electrophysiol J. 2008 Aug 01;8(3):175-81
references.pmid: 18679523
references.citation: Circ Arrhythm Electrophysiol. 2008 Apr;1(1):62-73
references.pmid: 19808395
references.citation: Am J Physiol. 1998 Nov;275(5):H1717-25
references.pmid: 9815079
references.citation: Cardiovasc Res. 2007 Jul 1;75(1):89-98
references.pmid: 17466958
references.citation: Curr Opin Cardiol. 2009 Jan;24(1):50-5
references.pmid: 19077816
references.citation: J Mol Cell Cardiol. 2002 Sep;34(9):1185-94
references.pmid: 12392892
references.citation: Cardiovasc Res. 1999 Oct;44(1):121-31
references.pmid: 10615396
references.citation: Circulation. 2007 Sep 25;116(13):1449-57
references.pmid: 17785620
references.citation: Br J Pharmacol. 2008 Aug;154(8):1619-30
references.pmid: 18536759
references.citation: Circulation. 2004 Aug 24;110(8):904-10
references.pmid: 15302796
references.citation: Nat Rev Drug Discov. 2006 Dec;5(12):1034-49
references.pmid: 17139288
references.citation: Cardiovasc Res. 1997 Jul;35(1):13-29
references.pmid: 9302343
references.citation: Circ Res. 1997 Jun;80(6):772-81
references.pmid: 9168779
references.citation: Physiol Rev. 2005 Oct;85(4):1205-53
references.pmid: 16183911
references.citation: J Cardiovasc Electrophysiol. 2006 Jun;17(6):648-54
references.pmid: 16836716
references.citation: Cardiovasc Res. 2005 Jul 1;67(1):69-76
references.pmid: 15949471
references.citation: Mol Pharmacol. 2008 Mar;73(3):940-8
references.pmid: 18079277
references.citation: N Engl J Med. 1989 Aug 10;321(6):406-12
references.pmid: 2473403
references.citation: J Atr Fibrillation. 2008 May 16;1(1):21
references.pmid: 28496569
references.citation: Heart Rhythm. 2005 Jul;2(7):758-72
references.pmid: 15992736
references.citation: Circulation. 2004 Oct 19;110(16):2299-306
references.pmid: 15477405
references.citation: Hum Mol Genet. 2006 Jul 15;15(14):2185-91
references.pmid: 16772329
references.citation: Heart Rhythm. 2008 Dec;5(12):1735-42
references.pmid: 19084813
references.citation: Prog Biophys Mol Biol. 1998;70(1):1-72
references.pmid: 9785957
references.citation: Circ Res. 1997 Dec;81(6):1045-52
references.pmid: 9400386
references.citation: J Cardiovasc Pharmacol. 2006 Jan;47(1):123-32
references.pmid: 16424796
references.citation: Am J Physiol. 1998 Jun;274(6):H1902-13
references.pmid: 9841518
references.citation: Circulation. 2004 Sep 28;110(13):1717-24
references.pmid: 15364815
references.citation: Cardiovasc Res. 2004 Apr 1;62(1):9-33
references.pmid: 15023549
references.citation: J Cardiovasc Electrophysiol. 2003 Aug;14(8):885-90
references.pmid: 12890054
references.citation: Heart Rhythm. 2008 Sep;5(9):1304-9
references.pmid: 18774108